Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. Forward-looking
statements inherently involve risks and uncertainties that could cause
actual results to differ materially from the forward-looking statements.
Factors that would cause or contribute to such differences include, but are
not limited to, continued acceptance for the Company's products in the
marketplace, competitive factors, changes in government reimbursement
procedures, dependence upon third-party vendors, and other risks discussed
in the Company's periodic and other filings with the Securities and
Exchange Commission. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for revisions
or changes after the date of this release. There can be no assurance that
the Company will recognize revenue related to its purchase orders and other
commitments in any particular period or at all because some of these
purchase orders and other commitments are subject to continge
|SOURCE Stereotaxis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved